Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound amino acid (20AA) is a parenteral nutrition solution containing a balanced mixture of 20 essential and non-essential amino acids, including branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine. It is designed to provide nutritional support, promote protein synthesis, and maintain nitrogen balance in patients with impaired oral intake or specific metabolic requirements. In clinical research, particularly in China, it is being investigated for its potential neuroprotective and metabolic support roles in Amyotrophic Lateral Sclerosis (ALS), often in combination with other agents like high-dose Vitamin B6. The 20AA formulation typically includes amino acids such as L-ornithine and L-citrulline in addition to the standard proteinogenic amino acids, which may assist in ammonia detoxification and urea cycle function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound amino acid (20AA).